CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 85 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Pembrolizumab 4mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05662527
NCT05662527Phase 2Completed
CompareCT.gov

Efficacy of Immunotherapy in Patients With MMR-deficient Localized Colon Cancer Scheduled for Curative Surgery - A Prospective, Phase II Study

Camilla Qvortrup·interventional·Posted Dec 22, 2022·Updated Aug 13, 2024

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab for Colon Cancer. Completed, enrolled 85 participants across 1 site.

Detailed Summary

The aim of this study is to evaluate the safety and efficacy of neoadjuvant treatment with pembrolizumab before colonic resection in patients with early-stage (I-III) deficient mismatch repair (dMMR) colon cancer (CC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColon Cancer
CountriesDenmark
CollaboratorsZealand University Hospital, Odense University Hospital, Vejle Hospital, Herlev and Gentofte Hospital, Bispebjerg Hospital, Aalborg University Hospital, Horsens Hospital, Randers Regional Hospital, Aarhus University Hospital

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedDec 22, 2022
Enrollment StartFeb 22, 2023
Primary CompletionJun 6, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 3.5 years ago

Interventions

Pembrolizumabdrug

One dosage of 4mg/kg (maximum of 400mg)